MINK THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
MINK THERAPEUTICS INC. - More news...
MINK THERAPEUTICS INC. - More news...
- MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
- MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
- MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
- MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
- MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
- MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
- MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
- MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
- MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
- MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
- MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
- MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
- MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
- MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
- MiNK Reports Second Quarter 2024 Results and Business Update
- MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
- MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
- MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
- MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
- MiNK Reports First Quarter 2024 Results
- MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
- MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
- MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
- MiNK Reports Fourth Quarter and Year-End 2023 Results
- MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
- MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
- First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
- MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
- MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
- ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
